1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Revvity, Inc.

Revvity, Inc.

RVTY
Revvity, Inc.US flagNew York Stock Exchange
130.22
USD
-0.41
- -
14.53BMarket Cap
Revvity, Inc.
RVTY
(New York Stock Exchange)

Recent

price

130.22

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
14.71
16.85
18.3
19.16
18.4
18.79
19.3
20.45
25.12
25.95
23.76
30.32
26.22
22.29
22.84
25.44
19.42
Revenue per Share
3.38
0.07
0.61
1.48
1.4
1.9
2.14
2.65
2.15
2.05
6.49
7.47
4.51
5.62
2.24
2.15
1.65
Basic EPS, GAAP
1.42
1.97
1.32
1.41
2.5
2.56
3.2
2.61
2.81
3.23
7.96
11.18
5.38
0.74
5.21
5.19
3.88
Free Cash Flow per Basic Share
0.29
0.28
0.28
0.28
0.28
0.28
0.28
0.28
0.28
0.28
0.28
0.26
0.28
0.28
0.29
0.29
0.21
Dividend per Share
16.64
16.28
16.86
17.71
18.16
18.84
19.65
22.68
23.37
25.32
33.33
56.57
58.46
63.79
63.55
64.57
- -
Book Value per Share
-0.03
-8.07
-6.2
-5.41
-6.51
-5.46
-4.69
-16.73
-14.17
-14.22
-9.61
-26.2
-19.6
-13.64
-11.92
-15.23
- -
Tangible Book Value per Share
116
114
115
113
112
112
110
110
111
111
112
126
126
123
121
112
112
Basic Weighted Avg Shares
1,702
1,919
2,105
2,158
2,070
2,105
2,116
2,257
2,778
2,884
2,663
3,828
3,312
2,751
2,755
2,856
2,182
Sales/Revenue/Turnover
10.37
5.61
9.61
12.14
8.62
12.57
14.17
13.66
12.06
13.57
32.56
32.88
22.43
10.93
12.59
12.49
12.35
Operating Margin (%)
89
111
125
127
110
105
100
105
181
214
202
311
427
432
428
405
310
Depreciation Expense
391
8
70
167
158
212
234
293
238
228
728
943
569
693
270
241
186
Net Income, GAAP
16.3
98.18
- -
- -
- -
9.59
11.62
47.12
7.84
3.96
21.19
26.1
21.35
1.9
10.46
10.58
6.77
Effective Tax Rate (%)
22.98
0.4
3.32
7.75
7.62
10.09
11.08
12.97
8.56
7.89
27.33
24.64
17.19
25.2
9.81
8.45
8.51
Profit Margin (%)
569
284
391
442
471
472
587
249
463
612
587
1,227
1,744
1,551
1,697
909
- -
Working Capital
424
945
939
932
1,045
1,012
1,045
1,789
1,877
2,210
1,798
5,127
4,093
3,311
3,302
2,779
- -
LT Debt
1,925
1,842
1,940
1,994
2,042
2,110
2,154
2,503
2,585
2,814
3,735
7,141
7,383
7,873
7,667
7,250
- -
Total Equity
6.51
0.08
- -
- -
- -
7.68
8.36
4.22
6.84
7.82
12.26
10.09
4.79
2.45
2.69
2.93
4.6
Return on Invested Capital (%)
17.81
0.32
- -
- -
- -
7.95
8.57
8.19
6.67
6.05
13.91
11.16
5.36
6.61
3.11
2.99
4.61
Return on Capital (%)
22
0.41
3.7
8.5
7.82
10.23
10.99
12.57
9.35
8.43
22.23
17.34
7.84
9.09
3.48
3.23
4.92
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
619
576
- -
LT Borrowings
2,631
2,632
- -
LT Finance Leases
148
142
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
112
112
112
Market Capitalization
10,863
9,780
12,420

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,240
2,128
- -
Cash, Cash Equivalents & STI
920
860
- -
Accounts Receivable, Net
745
691
- -
Inventories
379
388
- -
Total Current Liabilities
1,331
1,239
- -
Payables & Accruals
504
663
- -
ST Debt
619
576
- -
Deferred Revenue
160
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.63%
18.63%
-5.43%
Free Cash Flow
67.73%
100.18%
-7.22%
Net Income, GAAP
17.19%
-12.02%
-10.79%
Sales/Revenue/Turnover
4.36%
3.43%
3.67%
Total Cash Common Dividend
0.45%
1.11%
-4.8%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
650
692
684
729
2,755
2025
665
720
699
772
2,856
2026
711
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.45
0.77
0.78
2.24
2025
0.35
0.46
0.41
0.88
2.15
2026
0.36
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.07
0.07
0.07
0.29
2025
0.07
0.07
0.07
0.07
0.29
2026
0.07
- -
- -
- -
- -
Similar Companies
MDxHealth S.A. (MXDHF)
Thyrocare Technologies Limited (THYROCARE.NS)
DermTech, Inc. (DMTK)
Bangkok Genomics Innovation Public Company Limited (BKGI.BK)
Qiagen N.V. (QIA.DE)
Illumina, Inc. (ILMN)
Business
Revvity, Inc. is a life sciences and diagnostics company that provides health science solutions, technologies, expertise, and services delivering comprehensive workflows from discovery to development, diagnosis, and cure. The company offers instruments, reagents, assay platforms, software, detection and imaging technologies, and automated solutions such as liquid handlers and cell counters. Its product portfolio includes specialized brands like AlphaLISA and SureFire Ultra no-wash assays, Cellometer and Celigo automated cell counters, chemagic nucleic acid extraction systems, IVIS fluorescence and bioluminescence imaging platforms, LentiBOOST for lentiviral transduction, Vanadis noninvasive prenatal testing systems, and various other reagents, consumables, and assay kits targeting life science research and clinical diagnostics markets. Revvity’s diagnostics segment focuses on reproductive health, immunodiagnostics, applied genomics, and infectious disease detection, serving hospitals, medical labs, clinicians, and research professionals globally. Founded in 1937 and headquartered in Waltham, Massachusetts, Revvity emerged in 2023 following the split of PerkinElmer, Inc., retaining the life sciences and diagnostics businesses while the remaining segments were sold to private equity. Since its spinoff, Revvity has undergone significant strategic restructuring, including reorganizing its operating model effective fiscal year 2025 to integrate its Applied Genomics business into a newly formed Life Sciences Solutions unit. The company re-segmented its operations into Life Sciences Solutions and Software, and Diagnostics, which now encompasses Immunodiagnostics and Reproductive Health. Recent innovations include the launch of AI-driven software platforms like Signals One, the IDS i20 ChLIA analyzer, and advanced imaging systems such as the Quantum GX3 targeting specialized diagnostics markets. Revvity actively pursues cost discipline and operational synergies while investing in digital transformation and AI integration to enhance productivity and competitive positioning in precision diagnostics and life sciences research. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and clinical markets worldwide. Its comprehensive offerings support translational multi-omics technologies, biomarker identification, molecular imaging, immunoassays, molecular diagnostics, and genomic workflows with a focus on oncology, immunology, personalized medicine, and early disease detection. The company operates across North America, Europe, and other global regions, driven by innovation in reproductive health science, immune system disorder diagnostics, and genetic disorder testing. With a workforce exceeding 11,000 employees, Revvity continues to expand its product portfolio and technological capabilities to remain a leader in biotechnology, diagnostics, and life sciences markets.

Company News

Company News APIChatGPT

  • zacks.com

    Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

  • zacks.com

    What Makes Revvity (RVTY) a New Buy Stock

  • defenseworld.net

    Bank of New York Mellon Corp Invests $78.77 Million in Revvity Inc. $RVTY

  • zacks.com

    Is the Options Market Predicting a Spike in Revvity Stock?

  • gurufocus.com

    Revvity Inc (RVTY) Shares Surge 5.0% -- What GF Score of 78 Tells Investors

  • defenseworld.net

    Assenagon Asset Management S.A. Has $1.72 Million Stock Position in Revvity Inc. $RVTY

  • zacks.com

    Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs

  • defenseworld.net

    Revvity Inc. $RVTY Shares Acquired by Cetera Investment Advisers

  • businesswire.com

    Revvity to Present at Upcoming Investor Conferences

  • gurufocus.com

    Revvity to Present at Upcoming Investor Conferences

  • businesswire.com

    Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

  • marketbeat.com

    Revvity Q2 Earnings Call Highlights

  • zacks.com

    RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up

  • seekingalpha.com

    Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript

  • reuters.com

    Revvity raises annual profit, revenue forecasts on strong diagnostics demand

  • zacks.com

    Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates

  • gurufocus.com

    Is Revvity Inc (RVTY) Undervalued? Q2 Earnings Report Shows GAAP EPS at $0.48 and Revenue Reaches $730 Million -- GF Score 75/100

  • businesswire.com

    Revvity Announces Financial Results for the Second Quarter of 2026

  • businesswire.com

    Revvity Board Declares Quarterly Dividend

  • zacks.com

    Revvity to Report Q2 Earnings: What's in Store for the Stock?